Adriano Defini Andricopulo
CV Lattes
GoogleMyCitations
ResearcherID
ORCID
Universidade de São Paulo (USP). Instituto de Física de São Carlos (IFSC) (Institutional affiliation for the last research proposal) Birthplace: Brazil
graduate at Química Industrial from Universidade Federal de Santa Maria (1993), master's at Chemistry from Universidade Federal de Santa Catarina (1996) and ph.d. at Química Orgânica from Universidade Federal de Santa Catarina (1999). Has experience in Chemistry, acting on the following subjects: química medicinal, inibidores enzimáticos, relações entre a estrutura e a atividade (sar) and qsar. (Source: Lattes Curriculum)
- Converting natural product leads into structure- and ligand-based drug discovery campaigns against Leishmaniasis and Chagas' Disease, AP.TEM
Abstract
The lack of robustly validated drug targets has proved a significant barrier to the discovery of new treatments for visceral leishmaniasis and Chagas' disease. Furthermore, target deconvolution studies with active leads emerging from current small molecule phenotypic screening have confirmed that the same relatively few molecular targets are being hit repeatedly. This project aims to ...
- CIBFar - Center for Innovation in Biodiversity and Drug Discovery, AP.CEPID
Abstract
The Center for Innovation in Biodiversity and Drug Discovery (CIBFar) is a joint initiative resulting from existing collaborative research projects, including the Physics Institute of São Carlos (IFSC) and the School of Pharmaceutical Sciences of Ribeirão Preto at the University of São Paulo (USP), the Institute of Chemistry at the State University of São Paulo (UNESP), the Institute of...
- Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates, AP.BTA.TEM
Abstract
An International Cooperative Biodiversity Group (ICBG) with an interdisciplinary leadership team of physicians, pharmacologists, evolutionary biologists, and chemists will discover and develop therapeutic agents produced by Brazilian symbiotic bacteria. The team will target three therapeutic areas: 1) infectious fungal pathogens, 2) Chagas disease and leishmaniasis, and 3), cancers of t...
- Evaluation of activity of natural products ánd other compounds against multidrug resistant bacteria ánd their biofilms, BP.TT
- Discovery of new bioactive ligands with anticancer properties, BP.DR
Abstract
Cancer consists of a group of diseases characterized by the disordered growth of abnormal cells capable of invading numerous tissues and organs. The World Health Organization (WHO) considers it to be the second leading cause of death worldwide, being responsible for almost 10 million of deaths in 2018. Although chemotherapy relies on an important arsenal of drugs, treatments are associa...
- Understanding the biological function of natural products' scaffolds from databases for the design of active compounds for the treatment of infectious diseases, BP.PD
Abstract
Biodiversity provides exclusive chemical scaffolds for the design of active compounds and is the main source of drugs approved worldwide (67% are either a natural product, semi-synthetic derivative, macromolecule isolated from an organism or have a pharmacophore group inspired by natural products). Natural products are efficient models for medicinal chemistry because they comprise scaff...
(Only some records are available in English at this moment)
- Evaluation of activity of natural products and other compounds against multidrug resistant bacteria and their biofilms, BP.TT
- Chemoinformatics strategies for a series of antichagasic compounds, BP.IC
Abstract
Chagas disease is a neglected tropical disease that affects millions of people worldwide, mainly in Latin America, where it is endemic. According to the World Health Organization, Chagas disease is a high priority condition for the development of novel therapies. The available drugs are obsolete, and have low efficacy and outstanding toxicity. In this context, the discovery of novel tre...
- Design of inhibitors of the enzyme cruzain as drug candidates for the treatment of Chagas Disease, BP.DR
Abstract
Chagas' disease, also known as American trypanosomiasis, affects millions of people worldwide, mostly in Latin America, and is considered one of the neglected tropical diseases (NTD) of highest priority in the "Lead Discovery for Drugs for Tropical Infectious Diseases" program of the World Health Organization (WHO). The available drugs to fight the disease are extremely limited and have...
(Only some records are available in English at this moment)
- Pharmacokinetic and drug metabolism studies in drug discovery and development, BE.EP.DR
Abstract
Cruzain (EC 3.4.22.51) is the major cysteine protease from Trypanosoma cruzi, the Chagas disease etiological agent. Due to its biological relevance, this enzyme is considered one of the most relevant targets to develop new anti-chagasics, which is urgent once the available therapy is old and very toxic due to a blend of unsatisfactory side effects and lack of efficacy. In this way, the ...
- Structural studies of microtubule polymerization dynamics and its modulation by the action of anticancer drugs, BE.EP.DD
Abstract
Cancer is the name of a group of devastating diseases characterized by uncontrolled growth and multiplication of abnormal cells capable of invading nearby structures and spread in various regions of the body. These malignant cells fail to respond to control and defense mechanisms of the body, continually doubling in a disorderly manner and causing tumors. The world scenario caused by de...
| 2 / 2 | Ongoing research grants |
| 5 / 1 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 19 / 11 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 32 / 20 | All research grants and scholarships |
| Associated processes | |
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
| Publications | 7 |
| Citations | 76 |
| Cit./Article | 10.9 |
| Data from Web of Science | |
PAULI, IVANI; FERREIRA, LEONARDO G.; DE SOUZA, MARIANA L.; OLIVA, GLAUCIUS; FERREIRA, RAFAELA S.; DESSOY, MARCO A.; SLAFER, BRIAN W.; DIAS, LUIZ C.; ANDRICOPULO, ADRIANO D.. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors. Future Medicinal Chemistry, v. 9, n. 7, p. 641-657, MAY 2017. Web of Science Citations: 8. (13/07600-3, 13/25658-9, 11/13789-6)
DE FREITAS, LARISSA; VALLI, MARILIA; DAMETTO, ALESSANDRA C.; PENNACCHI, PAULA C.; ANDRICOPULO, ADRIANO D.; MARIA-ENGLER, SILVYA S.; BOLZANI, VANDERLAN S.. Advanced Glycation End Product Inhibition by Alkaloids from Ocotea paranapiacabensis for the Prevention of Skin Aging. Journal of Natural Products, v. 83, n. 3, SI, p. 649-656, MAR 27 2020. Web of Science Citations: 0. (19/05967-3, 14/50926-0, 13/07600-3)
SALUM, LIVIA BARROS; VALADARES, NAPOLEAO FONSECA. Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example. Journal of Computer-Aided Molecular Design, v. 24, n. 10, p. 803-817, OCT 2010. Web of Science Citations: 8. (07/07294-9)
ASSE JUNIOR, LEONARDO RANDER; KRONENBERGER, THALES; MAGALHAES SERAFIM, MATEUS SA; SOUSA, YAMARA VIANA; FRANCO, ISABELLA DRUMOND; VALLI, MARILIA; BOLZANI, VANDERLAN DA SILVA; MONTEIRO, GUSTAVO CLARO; BRUNO PRATES, JOAO LUCAS; KROON, ERNA GEESSIEN; et al. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors. Future Medicinal Chemistry, v. 12, n. 1, p. 51-68, JAN 2020. Web of Science Citations: 0. (19/05967-3, 14/50926-0, 13/07600-3)
DOS SANTOS, RICARDO N.; MORCOS, FARUCK; JANA, BIMAN; ANDRICOPULO, ADRIANO D.; ONUCHIC, JOSE N.. Dimeric interactions and complex formation using direct coevolutionary couplings. SCIENTIFIC REPORTS, v. 5, SEP 4 2015. Web of Science Citations: 29. (13/11950-0)
VALLI, MARILIA; ALTEI, WANESSA; DOS SANTOS, RICARDO N.; DE LUCCA, JR., EMILIO C.; DESSOY, MARCO A.; PIOLI, RENAN M.; COTINGUIBA, FERNANDO; CACHET, XAVIER; MICHEL, SYLVIE; FURLAN, MAYSA; et al. Synthetic Analogue of the Natural Product Piperlongumine as a Potent Inhibitor of Breast Cancer Cell Line Migration. Journal of the Brazilian Chemical Society, v. 28, n. 3, SI, p. 475-484, MAR 2017. Web of Science Citations: 7. (03/02176-7, 13/07600-3, 10/06741-4, 10/17329-7)
FERREIRA, RAFAELA S.; DESSOY, MARCO A.; PAULI, IVANI; SOUZA, MARIANA L.; KROGH, RENATA; SALES, ANA I. L.; OLIVA, GLAUCIUS; DIAS, LUIZ C.; ANDRICOPULO, ADRIANO D.. Synthesis, Biological Evaluation, and Structure-Activity Relationships of Potent Noncovalent and Nonpeptidic Cruzain Inhibitors as Anti-Trypanosoma cruzi Agents. Journal of Medicinal Chemistry, v. 57, n. 6, p. 2380-2392, MAR 27 2014. Web of Science Citations: 24. (12/02230-0, 13/07600-3, 10/16778-2)
(References retrieved automatically from State of São Paulo Research Institutions)
SANTOS, Ricardo Nascimento dos. Planejamento de moduladores de polimerização de microtúbulos com propriedades anticâncer, análise estrutural de macromoléculas e geração de uma base virtual de produtos naturais. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (10/06741-4)
MODA, Tiago Luiz. Modelagem In silico de propriedades farmacocinéticas para a avaliação de candidatos a novos fármacos. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (07/00440-0)
SALUM, Lívia de Barros. Planejamento de ligantes da tubulina com propriedades antitumorais. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (07/07294-9)
FERREIRA, Leonardo Luiz Gomes. Identificação de novos inibidores da enzima aldolase de Trypanosoma brucei. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (08/10727-7)
ALTEI, Wanessa Fernanda. Triagem biológica, identificação e planejamento de novos candidatos a agentes anticâncer a partir de produtos naturais e compostos sintéticos. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (09/15320-5)
PAULI, Ivaní. Planejamento de inibidores da enzima cruzaína candidatos a fármacos para o tratamento da doença de Chagas. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (11/13789-6)